Skip to main content
 CHANGE IN VISITATION GUIDELINES: Please read before visiting Rutgers Cancer Institute.
Menu

Print this page

KEYNOTE 365: Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC).

(1) Objective: To evaluate the safety and tolerability of the pembrolizumab combination therapy.
(2) Objective: To estimate PSA response rate of the pembrolizumab combination therapy. PSA response is defined as a reduction in

Protocol Number: 081611
Phase: Phase I/II
Applicable Disease Sites: Prostate
Drugs Involved: Olaparib
DOCETAXEL
Enzalutamide
Pembrolizumab (MK-3475)
PREDNISONE
Abiraterone
Principal Investigator: Tina Mayer M.D
Scope: National
Therapies Involved: Chemotherapy single agent systemic
Chemotherapy multiple agents systemic
Participating Institutions:
  • Rutgers Cancer Institute of New Jersey
Inclusion & Exclusion Criteria

Please note that we have obtained the inclusion and exclusion criteria information from the National Institutes of Health’s clinical trials web site ClinicalTrials.gov. The listed criteria may not necessarily reflect recent amendments to the protocol and the current criteria.

For further information about clinical trials, please contact us at 732-235-7356.